© Reuters. TCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, Mesothelioma
- TCR2 Therapeutics Inc (NASDAQ: TCRR) has announced topline results from the Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors.
- Gavo-cel demonstrated a disease control rate (DCR) of 77%. 28 of the 30 (93%) patients evaluable for efficacy experienced tumor regression of their target lesions, ranging in magnitude from 4% to 80%.
- Eight patients experienced target lesion regression greater than 30%, six of whom achieved a partial response (PR).
- One patient with cholangiocarcinoma was also considered to have achieved a PR, demonstrating that gavo-cel has induced responses in every tumor type tested.
- The overall response rate (ORR) among patients who received gavo-cel following lymphodepletion chemotherapy was 22% by BICR and 26% by investigator assessment.
- The median overall survival (OS) for patients with MPM was 11.2 months, whereas the median progression-free survival (PFS) for patients with MPM was 5.6 months.
- Gavo-cel was generally well tolerated, with a manageable adverse event profile up to DL5.
- Price Action: TCRR shares are up 9.47% at $1.85 during the premarket session on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.